Immunai
New York City, US · 3 known investors
Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
AI & Machine LearningBiotechData & Infrastructure
Investors · 3
In the news
- Miles Wang leaves OpenAI for a $2bn AI drug startupthenextweb.com · 2026
- Immunai uses AI to hunt for cancer, autoimmune targets in $15M Boehringer dealynetnews.com · 2026
- Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheimjpost.com · 2026
- Immunai signs up to $15 million research pact with Boehringer Ingelheim | Ctechcalcalistech.com · 2026
- BioCentury - Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215Mbiocentury.com · 2021
- U.S.-Israeli biotech startup Immunai raises $20 million | Reutersreuters.com · 2020